Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells.

Inflammation is a cancer hallmark that underlies cancer incidence and promotion, and eventually progression to metastasis. Therefore, adding an anti-inflammatory drug to standard cancer regiments may improve patient outcome. One such drug, aspirin (acetylsalicylic acid, ASA), has been explored for cancer chemoprevention and anti-tumor activity. Besides inhibiting the cyclooxygenase 2-prostaglandin axis, ASA's anti-cancer activities have also been attributed to nuclear factor ĸB (NFĸB) inhibition. Because prolonged ASA use may cause gastrointestinal toxicity, a prodrug strategy has been implemented successfully. In this prodrug design the carboxylic acid of ASA is masked and additional pharmacophores are incorporated. This protocol describes how we synthesized an aspirin-fumarate prodrug, GTCpFE, and characterized its inhibition of the NFĸB pathway in breast cancer cells and attenuation of the cancer stem-like properties, an important NFĸB-dependent phenotype. GTCpFE effectively inhibits the NFĸB pathway in breast cancer cell lines whereas ASA lacks any inhibitory activity, indicating that adding fumarate to ASA structure significantly contributes to its activity. In addition, GTCpFE shows significant anti-cancer stem cell activity by blocking mammosphere formation and attenuating the cancer stem cell associated CD44+CD24- immunophenotype. These results establish a viable strategy to develop improved anti-inflammatory drugs for chemoprevention and cancer therapy.

[1]  J. Frasor,et al.  Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein* , 2015, The Journal of Biological Chemistry.

[2]  J. Frasor,et al.  NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms , 2015, Molecular and Cellular Endocrinology.

[3]  J. Frasor,et al.  A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties , 2015, BMC Cancer.

[4]  J. Inoue,et al.  NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype , 2013, Nature Communications.

[5]  A. Baldwin,et al.  Canonical and Non-Canonical NF-κB Signaling Promotes Breast Cancer Tumor-Initiating Cells , 2013, Oncogene.

[6]  R. Weinberg,et al.  Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. , 2012, Cancer discovery.

[7]  Yuhong Yang,et al.  Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling* , 2012, The Journal of Biological Chemistry.

[8]  Kazuo Umezawa,et al.  ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer , 2012, Proceedings of the National Academy of Sciences.

[9]  C. Sostres,et al.  Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. , 2012, Best practice & research. Clinical gastroenterology.

[10]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[11]  N. Perkins,et al.  The diverse and complex roles of NF-κB subunits in cancer , 2012, Nature Reviews Cancer.

[12]  M. Lisanti,et al.  The role of breast cancer stem cells in metastasis and therapeutic implications. , 2011, The American journal of pathology.

[13]  M. Wicha,et al.  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.

[14]  M. Lisanti,et al.  The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. , 2010, Cancer research.

[15]  R. Hunt,et al.  Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. , 2010, Gastroenterology clinics of North America.

[16]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[17]  U. Mrowietz,et al.  Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation , 2010, Journal of Neuroinflammation.

[18]  J. Frasor,et al.  Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. , 2009, Cancer research.

[19]  I. Merfort,et al.  Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to limit airway smooth muscle cell cytokine secretion. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[20]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[21]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[22]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[23]  Sendurai A Mani,et al.  The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies , 2009, Journal of Mammary Gland Biology and Neoplasia.

[24]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[25]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[26]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[27]  M. Karin,et al.  IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells , 2007, Proceedings of the National Academy of Sciences.

[28]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[29]  H. Schumny,et al.  Next Generation , 2020 .

[30]  M. Vivanco,et al.  Growth and differentiation of progenitor/stem cells derived from the human mammary gland. , 2004, Experimental cell research.

[31]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.

[32]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[33]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  F. Luscinskas,et al.  Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. , 1996, Journal of immunology.

[35]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[36]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[37]  K. Wolff,et al.  Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. , 2002, Journal of immunology.

[38]  J. Geysen,et al.  Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. , 2001, The Journal of investigative dermatology.

[39]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[40]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.